Fate Therapeutics, Inc. (FATE)
NASDAQ: FATE · Real-Time Price · USD
2.795
+0.015 (0.54%)
At close: Jul 20, 2026, 4:00 PM EDT
2.800
+0.005 (0.16%)
After-hours: Jul 20, 2026, 7:48 PM EDT
Fate Therapeutics Employees
Fate Therapeutics had 161 employees as of December 31, 2025. The number of employees decreased by 20 or -11.05% compared to the previous year.
Employees
161
Change (1Y)
-20
Growth (1Y)
-11.05%
Revenue / Employee
$39,230
Profits / Employee
-$806,876
Market Cap
325.78M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 161 | -20 | -11.05% |
| Dec 31, 2024 | 181 | 0 | - |
| Dec 31, 2023 | 181 | -370 | -67.15% |
| Dec 31, 2022 | 551 | 102 | 22.72% |
| Sep 30, 2022 | 545 | 155 | 39.74% |
| Jun 30, 2022 | 542 | 186 | 52.25% |
| Mar 31, 2022 | 511 | 197 | 62.74% |
| Dec 31, 2021 | 449 | 170 | 60.93% |
| Sep 30, 2021 | 390 | 111 | 39.78% |
| Jun 30, 2021 | 356 | - | - |
| Mar 31, 2021 | 314 | 136 | 76.40% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Vanda Pharmaceuticals | 533 |
| Bicycle Therapeutics | 288 |
| Lyell Immunopharma | 161 |
| Foghorn Therapeutics | 106 |
| Neumora Therapeutics | 92 |
| OmniAb | 89 |
| Immuneering | 55 |
| Vicore Pharma Holding AB | 40 |
FATE News
- 11 days ago - Fate Therapeutics announces FDA clearance of FT839 IND application - TheFly
- 11 days ago - Fate Therapeutics Receives FDA Clearance of Investigational New Drug Application for FT839 Product Candidate - GlobeNewsWire
- 14 days ago - Fate Therapeutics to Present Preliminary Clinical Data of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Sclerosis at the ISSCR 2026 Annual Meeting - GlobeNewsWire
- 19 days ago - Fate Therapeutics to Participate in Upcoming Third Quarter 2026 Conferences - GlobeNewsWire
- 5 weeks ago - Fate Therapeutics Appoints Laura Hamill to Board of Directors - GlobeNewsWire
- 6 weeks ago - Fate Therapeutics Showcases Data from FT819 and FT839 Programs at the European Congress of Rheumatology Annual Meeting - GlobeNewsWire
- 6 weeks ago - Fate Therapeutics management to meet with Piper Sandler - TheFly
- 6 weeks ago - Fate Therapeutics Slides: Corporate presentation - Filings